mProX™ Human NRAS Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Hep3B;PLC

Target Classification

Kinase Cell Lines

Target Research Area

Autoimmune Research

Related Diseases

Ras-Associated Autoimmune Leukoproliferative Disorder; Noonan Syndrome 6

Gene ID

Human:4893

UniProt ID

Human:P01111

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NRAS (Neuroblastoma RAS viral oncogene homolog) is a gene that plays a role in various cancers, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), colorectal adenocarcinoma, and conjunctival melanoma. In AML, the DUSP1 signaling pathway, which is regulated by NRAS, has been found to be associated with cytarabine (Ara-C) resistance. Knockdown of DUSP1 sensitizes AML cells to Ara-C treatment. In MPNs, NRAS mutations are correlated with the progression of the disease. In colorectal adenocarcinoma, NRAS mutation status is one of the molecular markers used to guide therapy. In conjunctival melanoma, biomarkers such as NRAS mutations have been identified and may be targeted for future therapies. Overall, NRAS has implications in the sensitivity to treatment and progression of various cancers.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human NRAS Stable Cell Line (S01YF-1023-PY140). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

What is the impact of NRAS mutations on the efficacy of immunotherapy in melanoma? Mar 31 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

NRAS mutations can influence the response rates and prognosis of advanced melanoma treated with anti-PD-1 monotherapy. Mar 31 2023

chat Morgan Brown (Verified Customer)

Are there effective therapies for NRAS mutant melanoma? Mar 29 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Yes, there are therapeutic options focusing on combined inhibition of MAPK signaling and CDK4/6-driven cell cycle progression for NRAS mutant melanoma. Mar 29 2020

mProX™ Human NRAS Stable Cell Line

Made to Order Inquiry

Product Information

Product Properties

Protocols

Customer Reviews

Related Products by Target